CHAC1 in urological tumors: contextual dualism and therapeutic implications

CHAC1, a glutathione-degrading enzyme, governs context-dependent pathophysiological processes in urological malignancies through modulation of endoplasmic reticulum stress and ferroptotic pathways. In clear cell renal cell carcinoma (ccRCC), CHAC1 exhibits stage-specific functional duality: downregu...

Full description

Saved in:
Bibliographic Details
Main Authors: Deyu Wang, Yongquan Wan, Yunxiang Li, Yuan Ren, Jiakai Ma, Si Ge, Ziqiang Zeng, Zuoping Wang, Lei Zhen
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1610915/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849243197862051840
author Deyu Wang
Yongquan Wan
Yunxiang Li
Yuan Ren
Jiakai Ma
Si Ge
Ziqiang Zeng
Zuoping Wang
Lei Zhen
author_facet Deyu Wang
Yongquan Wan
Yunxiang Li
Yuan Ren
Jiakai Ma
Si Ge
Ziqiang Zeng
Zuoping Wang
Lei Zhen
author_sort Deyu Wang
collection DOAJ
description CHAC1, a glutathione-degrading enzyme, governs context-dependent pathophysiological processes in urological malignancies through modulation of endoplasmic reticulum stress and ferroptotic pathways. In clear cell renal cell carcinoma (ccRCC), CHAC1 exhibits stage-specific functional duality: downregulation in early-stage tumors correlates with adverse prognosis (suggesting tumor-suppressive activity), whereas elevated expression in advanced ccRCC (G3-G4/Stage III-IV) associates with increased mortality (indicating adaptive pro-survival adaptation). For prostate cancer, CHAC1 potentiates docetaxel cytotoxicity via coordinated induction of endoplasmic reticulum stress and ferroptosis, yet its suppression by cancer-associated fibroblast-derived exosomal miR-432-5p establishes therapy-reinforced chemoresistance. Mechanistically, CHAC1 intersects critical pathways by regulating redox homeostasis through glutathione catabolism, mediating potential crosstalk with androgen receptor signaling, and serving as an independent prognostic determinant in ccRCC (FPTOS_score model: HR = 2.028, 95% CI: 1.640-2.507). Notably, current evidence reveals no established link between CHAC1 and urothelial carcinoma pathogenesis. Further elucidation of CHAC1’s mechanistic intricacies and therapeutic targeting (e.g., CHAC1 agonists, exosomal miRNA antagonists) may advance precision management of urological tumors.
format Article
id doaj-art-e5a3115188e84be8a1d877d01a42d9dd
institution Kabale University
issn 2234-943X
language English
publishDate 2025-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj-art-e5a3115188e84be8a1d877d01a42d9dd2025-08-20T03:59:32ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-08-011510.3389/fonc.2025.16109151610915CHAC1 in urological tumors: contextual dualism and therapeutic implicationsDeyu WangYongquan WanYunxiang LiYuan RenJiakai MaSi GeZiqiang ZengZuoping WangLei ZhenCHAC1, a glutathione-degrading enzyme, governs context-dependent pathophysiological processes in urological malignancies through modulation of endoplasmic reticulum stress and ferroptotic pathways. In clear cell renal cell carcinoma (ccRCC), CHAC1 exhibits stage-specific functional duality: downregulation in early-stage tumors correlates with adverse prognosis (suggesting tumor-suppressive activity), whereas elevated expression in advanced ccRCC (G3-G4/Stage III-IV) associates with increased mortality (indicating adaptive pro-survival adaptation). For prostate cancer, CHAC1 potentiates docetaxel cytotoxicity via coordinated induction of endoplasmic reticulum stress and ferroptosis, yet its suppression by cancer-associated fibroblast-derived exosomal miR-432-5p establishes therapy-reinforced chemoresistance. Mechanistically, CHAC1 intersects critical pathways by regulating redox homeostasis through glutathione catabolism, mediating potential crosstalk with androgen receptor signaling, and serving as an independent prognostic determinant in ccRCC (FPTOS_score model: HR = 2.028, 95% CI: 1.640-2.507). Notably, current evidence reveals no established link between CHAC1 and urothelial carcinoma pathogenesis. Further elucidation of CHAC1’s mechanistic intricacies and therapeutic targeting (e.g., CHAC1 agonists, exosomal miRNA antagonists) may advance precision management of urological tumors.https://www.frontiersin.org/articles/10.3389/fonc.2025.1610915/fullCHAC1glutathione metabolismferroptosisendoplasmic reticulum stressprognostic biomarkerdrug resistance
spellingShingle Deyu Wang
Yongquan Wan
Yunxiang Li
Yuan Ren
Jiakai Ma
Si Ge
Ziqiang Zeng
Zuoping Wang
Lei Zhen
CHAC1 in urological tumors: contextual dualism and therapeutic implications
Frontiers in Oncology
CHAC1
glutathione metabolism
ferroptosis
endoplasmic reticulum stress
prognostic biomarker
drug resistance
title CHAC1 in urological tumors: contextual dualism and therapeutic implications
title_full CHAC1 in urological tumors: contextual dualism and therapeutic implications
title_fullStr CHAC1 in urological tumors: contextual dualism and therapeutic implications
title_full_unstemmed CHAC1 in urological tumors: contextual dualism and therapeutic implications
title_short CHAC1 in urological tumors: contextual dualism and therapeutic implications
title_sort chac1 in urological tumors contextual dualism and therapeutic implications
topic CHAC1
glutathione metabolism
ferroptosis
endoplasmic reticulum stress
prognostic biomarker
drug resistance
url https://www.frontiersin.org/articles/10.3389/fonc.2025.1610915/full
work_keys_str_mv AT deyuwang chac1inurologicaltumorscontextualdualismandtherapeuticimplications
AT yongquanwan chac1inurologicaltumorscontextualdualismandtherapeuticimplications
AT yunxiangli chac1inurologicaltumorscontextualdualismandtherapeuticimplications
AT yuanren chac1inurologicaltumorscontextualdualismandtherapeuticimplications
AT jiakaima chac1inurologicaltumorscontextualdualismandtherapeuticimplications
AT sige chac1inurologicaltumorscontextualdualismandtherapeuticimplications
AT ziqiangzeng chac1inurologicaltumorscontextualdualismandtherapeuticimplications
AT zuopingwang chac1inurologicaltumorscontextualdualismandtherapeuticimplications
AT leizhen chac1inurologicaltumorscontextualdualismandtherapeuticimplications